Oncotarget最新文献_第2页

Beyond the hype: Navigating bias in AI-driven cancer detection. 超越炒作：在人工智能驱动的癌症检测中消除偏见。

Oncotarget Pub Date : 2024-11-07 DOI: 10.18632/oncotarget.28665

Yashbir Singh, Heenaben Patel, Diana V Vera-Garcia, Quincy A Hathaway, Deepa Sarkar, Emilio Quaia

引用次数: 0

Retraction: MicroRNA-20a-5p promotes colorectal cancer invasion and metastasis by downregulating Smad4. 撤回：MicroRNA-20a-5p 通过下调 Smad4 促进结直肠癌的侵袭和转移

Oncotarget Pub Date : 2024-11-07 DOI: 10.18632/oncotarget.28669

Dantong Cheng, Senlin Zhao, Huamei Tang, Dongyuan Zhang, Hongcheng Sun, Fudong Yu, Weiliang Jiang, Ben Yue, Jingtao Wang, Meng Zhang, Yang Yu, Xisheng Liu, Xiaofeng Sun, Zongguang Zhou, Xuebin Qin, Xin Zhang, Dongwang Yan, Yugang Wen, Zhihai Peng

引用次数: 0

Understanding the interplay between extracellular matrix topology and tumor-immune interactions: Challenges and opportunities. 了解细胞外基质拓扑结构与肿瘤免疫相互作用之间的相互作用：挑战与机遇。

Oncotarget Pub Date : 2024-11-07 DOI: 10.18632/oncotarget.28666

Yijia Fan, Alvis Chiu, Feng Zhao, Jason T George

{"title":"Understanding the interplay between extracellular matrix topology and tumor-immune interactions: Challenges and opportunities.","authors":"Yijia Fan, Alvis Chiu, Feng Zhao, Jason T George","doi":"10.18632/oncotarget.28666","DOIUrl":"10.18632/oncotarget.28666","url":null,"abstract":"Modern cancer management comprises a variety of treatment strategies. Immunotherapy, while successful at treating many cancer subtypes, is often hindered by tumor immune evasion and T cell exhaustion as a result of an immunosuppressive tumor microenvironment (TME). In solid malignancies, the extracellular matrix (ECM) embedded within the TME plays a central role in T cell recognition and cancer growth by providing structural support and regulating cell behavior. Relative to healthy tissues, tumor associated ECM signatures include increased fiber density and alignment. These and other differentiating features contributed to variation in clinically observed tumor-specific ECM configurations, collectively referred to as Tumor-Associated Collagen Signatures (TACS) 1-3. TACS is associated with disease progression and immune evasion. This review explores our current understanding of how ECM geometry influences the behaviors of both immune cells and tumor cells, which in turn impacts treatment efficacy and cancer evolutionary progression. We discuss the effects of ECM remodeling on cancer cells and T cell behavior and review recent in silico models of cancer-immune interactions.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"768-781"},"PeriodicalIF":0.0,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11546212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Initiation of tumor dormancy by the lymphovascular embolus. 淋巴管栓塞引发肿瘤休眠

Oncotarget Pub Date : 2024-10-11 DOI: 10.18632/oncotarget.28658

Yin Ye, Justin Wang, Michael G Izban, Billy R Ballard, Sanford H Barsky

{"title":"Initiation of tumor dormancy by the lymphovascular embolus.","authors":"Yin Ye, Justin Wang, Michael G Izban, Billy R Ballard, Sanford H Barsky","doi":"10.18632/oncotarget.28658","DOIUrl":"10.18632/oncotarget.28658","url":null,"abstract":"Cancer dormancy followed by recurrence remains an enigma in cancer biology. Since both local and systemic recurrences are thought to emanate from dormant micrometastasis which take origin from lymphovascular tumor emboli we wondered whether the process of dormancy might initiate within lymphovascular emboli. This study combines experimental studies with a patient-derived xenograft (PDX) of inflammatory breast cancer (Mary-X) that spontaneously forms spheroids in vitro and budding lymphovascular tumor emboli in vivo with observational studies utilizing tissue microarrays (TMAs) of human breast cancers. In the experimental studies, Mary-X during both lymphovascular emboli formation in vivo and spheroidgenesis in vitro exhibited decreased proliferation, a G0/G1 cell cycle arrest and decreased mTOR signaling. This induction of dormancy required calpain-mediated E-cadherin proteolysis and was mediated by decreased P13K signaling, resulting in decreased mTOR activity. In observational human breast cancer studies, increased E-cadherin immunoreactivity due to increased E-cad/NTF-1 but both decreased Ki-67 and mTOR activity was observed selectively and differentially within the lymphovascular tumor emboli. Both our experimental as well as observational studies indicate that in vivo lymphovascular tumor emboli and their in vitro spheroid equivalent initiate dormancy through these pathways.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"726-740"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor. BRAF V600E突变转移性恶性胶质瘤患者对安戈非尼加比尼替尼治疗的完全应答。

Oncotarget Pub Date : 2024-10-11 DOI: 10.18632/oncotarget.28654

Marta Arregui, Antonio Calles, María Del Mar Galera, Ana Gutiérrez, Carlos López-Jiménez, Carolina Agra, Adriana Fernández, Natalia Gutiérrez, María de Toro, Rosa Álvarez

引用次数: 0

A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy. 一例 KRAS G12C 突变的腺鳞癌胰腺癌患者对免疫疗法的特殊反应。

Oncotarget Pub Date : 2024-10-11 DOI: 10.18632/oncotarget.28659

Murtaza Ahmed, Brent K Larson, Arsen Osipov, Nilofer Azad, Andrew Hendifar

{"title":"A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.","authors":"Murtaza Ahmed, Brent K Larson, Arsen Osipov, Nilofer Azad, Andrew Hendifar","doi":"10.18632/oncotarget.28659","DOIUrl":"10.18632/oncotarget.28659","url":null,"abstract":"Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths, with adenosquamous carcinoma of the pancreas (ASCP), a rare variant, representing 1-10% of cases. Standard chemotherapy trials for pancreatic cancer exclude ASCP, leaving its optimal treatment uncertain. This report describes a 68-year-old male with metastatic ASCP and a KRAS G12C mutation, progressing through multiple lines of systemic therapy, including targeted inhibition of KRAS G12C. Notably, the patient exhibited a robust response to single-agent immune checkpoint inhibition (ICI) with pembrolizumab, despite intact mismatch repair proteins. The limited success of traditional therapies in pancreatic cancer, coupled with the rarity of ASCP, presents a challenge in establishing effective treatment strategies. While KRAS G12C inhibitors demonstrated modest benefits, this case highlights the remarkable response to ICI in a patient with squamous histology. The distinct tumor microenvironment of ASCP, characterized by squamous differentiation, may contribute to this exceptional response. This underscores the need for further research and clinical trials focused on ICI in ASCP, with an ongoing multi-center phase 2 trial investigating outcomes in this specific subset.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"741-747"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gene regulatory network and signalling pathway rewiring: How blood cancer cells shift their shapes to evade drug treatment. 基因调控网络和信号通路重新布线：血癌细胞如何改变形状以逃避药物治疗？

Oncotarget Pub Date : 2024-10-11 DOI: 10.18632/oncotarget.28662

Constanze Bonifer, Peter N Cockerill

引用次数: 0

Correction: The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. 更正：抗 HER3（ErbB3）治疗性抗体 9F7-F11 通过 JNK1/2 依赖性 ITCH/AIP4 激活诱导肿瘤中 HER3 泛素化和降解。

Oncotarget Pub Date : 2024-10-11 DOI: 10.18632/oncotarget.28664

Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Christel Larbouret, Marie-Alix Poul, Philippe Mondon, Gerry Melino, André Pèlegrin, Thierry Chardès

引用次数: 0

Retraction: Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma. 撤回：在骨肉瘤临床前模型中整合对微管蛋白结合剂 Eribulin 的反应和抵抗机制。

Oncotarget Pub Date : 2024-10-11 DOI: 10.18632/oncotarget.28663

Valerie B Sampson, Nancy S Vetter, Wendong Zhang, Pratima U Patil, Robert W Mason, Erika George, Richard Gorlick, Edward A Kolb

引用次数: 0

Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC. DLL3、ASC1、TTF-1和Ki-67表达之间的关系：SCLC精准医疗的第一步。

Oncotarget Pub Date : 2024-10-11 DOI: 10.18632/oncotarget.28660

Samuel Silva, Juliana C Sousa, Cleto Nogueira, Raquel Feijo, Francisco Martins Neto, Laura Cardoso Marinho, Guilherme Sousa, Valeria Denninghoff, Fabio Tavora

{"title":"Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC.","authors":"Samuel Silva, Juliana C Sousa, Cleto Nogueira, Raquel Feijo, Francisco Martins Neto, Laura Cardoso Marinho, Guilherme Sousa, Valeria Denninghoff, Fabio Tavora","doi":"10.18632/oncotarget.28660","DOIUrl":"10.18632/oncotarget.28660","url":null,"abstract":"This study presents an observational, cross-sectional analysis of 64 patients diagnosed with small cell lung cancer (SCLC) at a reference laboratory for thoracic pathology between 2022 and 2024. The primary objective was to evaluate the expression of Delta-like ligand 3 (DLL3) and other neuroendocrine markers such as Chromogranin, and Synaptophysin, utilizing both traditional immunohistochemistry and digital pathology tools. Patients were primarily older adults, with a median age of over 71, and most biopsies were obtained from lung parenchyma. Immunohistochemistry (IHC) was performed using specific monoclonal antibodies, with DLL3 showing variable expression across the samples. Notably, DLL3 was expressed in 72.3% of the cases, with varied intensities and a semi-quantitative H-score applied for more nuanced analysis. ASCL1 was expressed in 97% of cases, with the majority considered low-expressors. Only 11% had high expression. TTF-1, traditionally not a conventional marker for the diagnosis of SCLC, was positive in half of the cases, suggesting its potential as a biomarker. The study underscores the significant variability in the expression of neuroendocrine markers in SCLC, with implications for both diagnosis and potential therapeutic targeting. DLL3, particularly, shows promise as a therapeutic target due to its high expression rate in the cohort. The use of digital pathology software QuPath enhanced the accuracy and depth of analysis, allowing for detailed morphometric analysis and potentially informing more personalized treatment approaches. The findings emphasize the need for further research into the role of these markers in the management and treatment of SCLC, considering the poor prognosis and high mortality rate observed in the cohort.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"750-763"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0